A New Framework for Alzheimer's Disease
In 2014, Dr. Dale Bredesen of UCLA published a landmark paper describing the first program to demonstrate reversal of cognitive decline in patients with Alzheimer's disease, MCI, and subjective cognitive impairment — treating 9 of 10 patients with meaningful improvement.
The central insight of Bredesen's work is that Alzheimer's disease is not a single-variable disease. He describes it as a "leaky roof with 36 holes" — patching one will not stop the leak. Conventional pharmaceutical approaches have largely failed because they target one pathway (e.g., amyloid clearance alone) in an extremely complex, multifactorial disease.
His solution: a comprehensive, personalized, systems-based approach called MEND (Metabolic Enhancement for Neurodegeneration), later refined into the ReCODE (Reversal of Cognitive Decline) protocol. Rather than asking "what disease does this patient have?", it asks "what are all the factors driving this patient's cognitive decline, and can we address each one?"
The 2014 Paper: Key Results
A 67-year-old woman with 2-year progressive memory loss, APOE4/4 genotype (highest genetic risk), and family history of Alzheimer's. She had abandoned her demanding job due to cognitive difficulties and feared she was developing the disease her mother had died from. She began the MEND protocol in 2012.
After 6 months, her memory had improved substantially. After 2.5 years, she remains without subjective or objective cognitive decline — she returned to her work with improved performance. Her neuropsychological testing showed marked improvement across all domains.
The "Cognoscopy" — Bredesen's Evaluation Framework
Before treatment, every patient undergoes a comprehensive evaluation he calls a cognoscopy. This includes:
Cognitive Testing
- ▸ MoCA (Montreal Cognitive Assessment)
- ▸ CNS Vital Signs or MoCA-MCI battery
- ▸ Volumetric MRI brain (hippocampal volume)
- ▸ Optional: amyloid PET, tau PET, FDG-PET
Genetics & Biomarkers
- ▸ APOE genotype (ε4 status)
- ▸ Comprehensive metabolic panel (25+ markers)
- ▸ Inflammatory markers: CRP, homocysteine
- ▸ Hormonal panel, thyroid, vitamin D, B12
Three Subtypes of Alzheimer's Disease
One of Bredesen's most clinically important contributions is the recognition that "Alzheimer's disease" is not a single entity. He identifies three distinct subtypes, each with different drivers and therefore different therapeutic priorities.
Driven by chronic neuroinflammation. Strongly associated with APOE ε4 genotype. Elevated CRP, high homocysteine, evidence of systemic inflammation. Often presents earlier and progresses faster.
Target: anti-inflammatory diet, omega-3s, curcumin, oral health, CRP normalization
Driven by loss of trophic support — insufficient hormones (estrogen, testosterone, thyroid), growth factors (NGF, BDNF), and nutritional support. Later onset, slower progression. Low inflammation.
Target: hormone optimization, NGF support, B12, sleep, exercise
Driven by exposure to biotoxins (mold, mycotoxins), heavy metals (mercury, lead), organic chemicals, or infectious agents. Often presents in younger patients. Non-amnestic presentation common.
Target: detoxification, mold remediation, chelation, antifungals as indicated
The APP Signaling Model
Bredesen's laboratory research over 20+ years led to a fundamental reframing of amyloid precursor protein (APP) function. APP is processed at two competing cleavage sites:
The MEND protocol works to shift the balance back toward the α-secretase pathway by providing the hormonal, metabolic, and trophic inputs that signal neurons to "stay alive and grow" rather than "downsize and die."
Why Monotherapy Fails
This framework explains why every single-agent drug trial for Alzheimer's disease has failed to demonstrate meaningful cognitive benefit at the population level. Even if drug X successfully reduces amyloid, the 35 other drivers of APP's shift toward the amyloidogenic pathway remain untreated. The net signal to neurons remains "downsize."
MEND Intervention Table
The table below is drawn directly from Bredesen's 2014 publication (Table 1) and the accompanying intervention protocol, with clinical rationale expanded for educational use. Each row represents one "hole" in the leaky roof.
| # | Target / Goal | Intervention / Approach | Mechanism / Rationale | Ref |
|---|---|---|---|---|
| 1 | Lifestyle Optimize diet |
Low-glycemic, low-inflammatory, low-grain diet (Mediterranean-ketogenic hybrid; avoid processed sugars, refined carbohydrates) | Reduces insulin resistance and systemic inflammation, two of the strongest modifiable drivers of AD pathology | General |
| 2 | Lifestyle Enhance autophagy / ketogenesis |
12-hour overnight fast; no food within 3 hrs of bedtime; aim for mild nutritional ketosis | Lowers insulin levels; promotes amyloid-β clearance via autophagy; ketones provide alternative neuronal fuel bypassing insulin resistance | Metabolic |
| 3 | Lifestyle Reduce stress |
Personalized stress management: yoga, meditation, music, social connection, nature exposure | Chronic cortisol elevation damages the hippocampus directly; stress axis dysregulation worsens AD progression | — |
| 4 | Sleep Optimize sleep |
8 hrs nightly; melatonin 0.5 mg qHS; tryptophan 500 mg PO 3×/wk if early awakening; screen and treat sleep apnea | Sleep is required for glymphatic amyloid clearance; chronic sleep deprivation is an independent AD risk factor; OSA causes nocturnal hypoxia and accelerates neurodegeneration | [36] |
| 5 | Lifestyle Exercise |
30–60 min daily, 4–6 days/week; combination of aerobic and resistance training | Aerobic exercise increases BDNF (brain-derived neurotrophic factor); improves cerebral blood flow; resistance training improves insulin sensitivity; both stimulate neurogenesis | [37, 38] |
| 6 | Lifestyle Cognitive stimulation |
Cognitive exercises or Posit Science-type programs (BrainHQ); learning new skills; social engagement. Correct hearing deficit with hearing aids or sound amplifiers (strong level of evidence) | Promotes synaptic plasticity and cognitive reserve; use-dependent neuronal survival | [39] |
| 7 | Biomarker Homocysteine <7 µmol/L |
Methyl-B12 (methylcobalamin), methyl-folate (5-MTHF), P5P (active B6); add trimethylglycine (TMG) if homocysteine remains elevated | Elevated homocysteine is directly neurotoxic and endothelially damaging; normalizing it is strongly neuroprotective; supports the methylation cycle and DNA repair | [40] |
| 8 | Biomarker Serum B12 >500 pg/mL |
Methyl-B12 (methylcobalamin) supplementation; avoid cyanocobalamin; check methylmalonic acid if borderline | B12 deficiency is a reversible cause of cognitive decline and neurodegeneration; supports myelin, methylation, and neuronal function; common in older adults and metformin users | [41] |
| 9 | Biomarker CRP <1.0 mg/L; A/G ratio >1.5 |
Anti-inflammatory diet; curcumin 1–2g/day (with piperine); omega-3 (DHA/EPA) 2–3g/day; oral hygiene optimization (periodontal disease is an AD risk factor) | Neuroinflammation is a central driver of AD pathology; CRP and albumin/globulin ratio are accessible clinical markers; periodontal pathogens have been found in AD brain tissue | — |
| 10 | Biomarker Fasting insulin <7; HbA1c <5.5% |
Per diet protocol above; consider metformin if T2DM; avoid prolonged sedentary time | Alzheimer's has been described as "Type 3 Diabetes"; insulin resistance in the brain impairs neuronal glucose metabolism, a hallmark of AD on FDG-PET | — |
| 11 | Hormonal Hormone optimization |
Optimize free T3/T4 (reverse T3/free T3 ratio), estradiol, testosterone, progesterone, pregnenolone, DHEA-S, cortisol; use bioidentical hormones where indicated | Hormones are essential trophic signals for neuronal survival; estrogen promotes α-secretase (protective) cleavage of APP; thyroid hormone regulates neuronal metabolism; low testosterone is an independent dementia risk factor in men | [5, 42] |
| 12 | Supplement GI health |
Gut repair if needed; prebiotic fiber; probiotic supplementation; address dysbiosis and leaky gut | The gut-brain axis is bidirectional; gut dysbiosis promotes systemic inflammation and neuroinflammation; LPS from gram-negative bacteria crosses the blood-brain barrier in leaky gut states | — |
| 13 | Supplement Reduce amyloid-β |
Curcumin (lipophilic formulation preferred); Ashwagandha (withanolides) | Both agents have demonstrated amyloid-β disaggregation and reduced production in in vitro and animal studies; curcumin is also anti-inflammatory and antioxidant | [43–45] |
| 14 | Supplement Cognitive enhancement |
Bacopa monnieri (standardized extract); magnesium threonate (MgT) — the only form that crosses the blood-brain barrier efficiently | Bacopa improves memory and reduces anxiety in clinical trials; magnesium threonate increases synaptic density and improves learning and working memory in animal models | [46, 47] |
| 15 | Biomarker Vitamin D3: 50–100 ng/mL (25-OH-D3) |
Vitamin D3 2000–5000 IU/day + Vitamin K2 (MK-7) to prevent hypercalcemia; monitor levels | Vitamin D receptors are expressed throughout the brain; deficiency is associated with cognitive decline; vitamin D supports immune regulation, neuroprotection, and anti-amyloid pathways; K2 required to direct calcium to bone | [48] |
| 16 | Supplement Increase NGF |
Lion's mane mushroom (Hericium erinaceus) — stimulates NGF production; ALCAR (acetyl-L-carnitine) — mitochondrial support and NGF sensitivity | Nerve Growth Factor (NGF) is essential for the survival and function of cholinergic neurons in the basal forebrain — the primary system affected in early AD. NGF deficiency drives neuronal atrophy | [49, 50] |
| 17 | Supplement Synaptic support |
Citicoline (CDP-choline) 250–500 mg/day; DHA (docosahexaenoic acid) 1–2g/day | Citicoline provides choline for acetylcholine synthesis and phosphatidylcholine for membrane repair; DHA is the dominant structural omega-3 in brain tissue; both are required for synaptogenesis | [51] |
| 18 | Supplement Optimize antioxidants |
Mixed tocopherols and tocotrienols (full-spectrum vitamin E); selenium 200 mcg/day; blueberries (fresh/frozen); NAC (N-acetylcysteine); vitamin C; alpha-lipoic acid | Oxidative stress is a proximal cause of neuronal damage in AD; the brain is disproportionately vulnerable due to high metabolic activity and lipid content; comprehensive antioxidant coverage targets multiple ROS pathways | [52] |
| 19 | Biomarker Optimize Zn:Cu ratio |
Adjust supplementation based on plasma zinc and copper levels; monitor periodically | Both zinc and copper are required for superoxide dismutase (SOD) activity; dysregulated Zn:Cu promotes amyloid aggregation; excess free copper is neurotoxic | [53] |
| 20 | Sleep Ensure nocturnal oxygenation |
Evaluate for and treat obstructive sleep apnea (polysomnography; CPAP or oral appliance) | OSA causes intermittent hypoxia that accelerates hippocampal atrophy; glymphatic clearance of amyloid requires adequate sleep architecture; OSA is a treatable and reversible AD risk factor | [54] |
| 21 | Supplement Mitochondrial support |
CoQ10/ubiquinol 200–400 mg; alpha-lipoic acid; PQQ (pyrroloquinoline quinone); NAC; ALCAR; selenium; zinc; resveratrol; vitamin C; thiamine (B1) | Mitochondrial dysfunction is an early and central feature of AD; neurons have extraordinarily high energy demands; supporting mitochondrial electron transport and reducing mitochondrial oxidative stress directly protects neurons | [55] |
| 22 | Supplement Increase focus / acetylcholine |
Pantothenic acid (Vitamin B5) 500 mg/day | Pantothenic acid is required for CoA synthesis, which is essential for acetylcholine production; supports the cholinergic system that is selectively lost in early AD | — |
| 23 | Supplement Increase SIRT1 activity |
Resveratrol 100–500 mg/day (preferably with food and fat for absorption; or NMN/NR for upstream NAD+ support) | SIRT1 is a longevity-associated deacetylase that activates neuroprotective pathways, reduces amyloid production, and promotes mitochondrial biogenesis; reduced in AD brain tissue | [32] |
| 24 | Biomarker Exclude heavy metal toxicity |
Test mercury (RBC or urine), lead (blood), cadmium; chelation therapy (DMSA, DMPS) if elevated; avoid high-mercury fish | Mercury and lead are potent neurotoxins that contribute to Type 3 ("toxic") AD; mercury inhibits key enzymes and promotes tau phosphorylation; sources include dental amalgams, large fish, and occupational exposure | — |
| 25 | Supplement MCT / ketone support |
Coconut oil 1–2 tbsp/day; or Axona (caprylidene); or MCT oil; or exogenous ketone supplements | In AD, glucose metabolism is impaired (hypometabolism on FDG-PET) but ketone metabolism is preserved; MCTs provide medium-chain fatty acids that are rapidly converted to ketones, providing alternative neuronal fuel | [56] |
Reference numbers correspond to citations in Bredesen DE. Aging. 2014;6(9):707–717. Full text: PMC4221920
Target Lab Values for the MEND Protocol
The MEND protocol requires a far broader laboratory evaluation than standard dementia workup. These are Bredesen's recommended target values — many represent more aggressive optimization than standard reference ranges.
| Biomarker | Bredesen Target | Standard Range | Intervention if Low/High |
|---|---|---|---|
| Fasting glucose | <90 mg/dL | 70–99 mg/dL (normal) | Dietary modification, exercise, time-restricted eating |
| HbA1c | <5.5% | <5.7% (normal) | Low-glycemic diet, intermittent fasting |
| Fasting insulin | <7 µIU/mL | <25 µIU/mL (normal) | Diet, exercise, metformin if T2DM |
| hs-CRP | <1.0 mg/L | <3.0 mg/L (low risk) | Anti-inflammatory diet, omega-3, curcumin, dental care |
| Homocysteine | <7 µmol/L | <15 µmol/L (normal) | Methyl-B12, methyl-folate (5-MTHF), P5P, TMG |
| Vitamin B12 (serum) | >500 pg/mL | 200–900 pg/mL (normal) | Methyl-B12 supplementation; check MMA |
| 25-OH Vitamin D3 | 50–100 ng/mL | ≥30 ng/mL (sufficient) | Vitamin D3 2000–5000 IU/day + K2 MK-7 |
| Free T3 | 3.2–4.2 pg/mL | 2.3–4.2 pg/mL (normal) | Thyroid hormone optimization; address reverse T3 |
| Reverse T3 / Free T3 ratio | <20 | Variable | Evaluate adrenal function; selenium; liothyronine if needed |
| DHEA-S | Male 350–500 µg/dL; Female 275–400 µg/dL | Age-dependent | DHEA supplementation 25–50 mg/day with monitoring |
| Estradiol (female) | 50–100 pg/mL (postmenopause: 50–80) | Variable by age | Bioidentical estradiol transdermal; progesterone if uterus intact |
| Free testosterone (male) | 6.5–15 ng/dL | Age-dependent | Bioidentical testosterone; address contributing factors |
| Pregnenolone | 50–100 ng/dL | Age-dependent (declines with age) | Pregnenolone supplementation 50–100 mg/day; monitor levels |
| Omega-3 index | >8% | >8% (optimal) | DHA/EPA 2–3g/day; preferably phospholipid form (krill) |
| Albumin/Globulin ratio | >1.5 | >1.1 (normal) | Address protein intake, inflammation, liver function |
| Heavy metals (Hg, Pb, Cd) | Below detectable / within normal | Reference lab-dependent | Chelation if elevated; identify and remove sources |
Vascular Dementia & the Endothelial Glycocalyx
Vascular cognitive impairment and dementia (VCID) is driven by endothelial dysfunction, chronic inflammation, and microvascular disease — all of which compromise blood flow to the brain. A new generation of glycocalyx-targeted interventions is showing promise for endovascular disease reversal and cerebrovascular protection.
The brain consumes 20% of the body's oxygen and glucose despite representing only 2% of body weight. It has essentially no metabolic reserve — interruptions to cerebral blood flow cause neuronal dysfunction within seconds and neuronal death within minutes. Chronic microvascular disease is a silent, progressive contributor to cognitive decline even in patients without overt stroke.
The endothelial glycocalyx (EGX) is the microscopically thin, gel-like lining that coats the inner surface of every blood vessel in the body — including the 60,000 miles of microvessels supplying the brain. It is the first barrier between blood and the vessel wall, and its integrity is fundamental to:
- ▸ Preventing atherosclerotic plaque formation
- ▸ Regulating vascular permeability
- ▸ Triggering nitric oxide production
- ▸ Inhibiting leukocyte adhesion and inflammation
- ▸ Maintaining blood-brain barrier integrity
- ▸ Supporting microcirculation to neurons
- ▸ Preventing cholesterol adhesion to arterial walls
- ▸ Anti-thrombotic and anti-coagulation properties
Glycocalyx-Targeted Supplements
Until recently, no agent was known to restore the endothelial glycocalyx once degraded. Two nutraceuticals — Arterosil HP and ReVasca — represent the first class of glycocalyx-regenerating compounds (GRCs) and are showing early but promising results in vascular disease reversal.
- MonitumRS® — proprietary rhamnan sulfate extract from rare green seaweed Monostroma nitidum; mimics native glycocalyx glycosaminoglycans and integrates into damaged EGX to restore structural integrity
- Enhanced with a blend of 22 fruits, vegetables, and green tea extracts for synergistic antioxidant and anti-inflammatory vascular benefit
- Structurally restores degraded heparan sulfate chains on the EGX surface
- Inhibits cholesterol and LDL adhesion to the endothelial wall
- Reduces leukocyte adhesion and vascular inflammation
- Supports nitric oxide bioavailability and vasodilation
- Heparin-mimicking activity — mild anticoagulant effect
- Addresses endothelial dysfunction upstream of white matter hyperintensities and microvascular disease
- May reduce cerebrovascular risk factors driving VCID
- Complementary to MEND protocol items 7–10 (homocysteine, inflammation, insulin resistance)
- Hyaluronic acid — constitutes ~90% of the human EGX; directly replaces degraded glycocalyx components
- Vascaman™ (Acemannan) — polysaccharide from aloe vera; supports glycocalyx repair, nitric oxide production, and gut microbiome integrity
- Fucoidan — from brown seaweed; anti-inflammatory, antioxidant, EGX-supportive
- L-Citrulline & ViNitrox™ — nitric oxide precursors for vasodilation and endothelial function
- Directly provides hyaluronic acid — the primary structural component of the EGX — as a building block for glycocalyx regeneration
- Targets microvascular system (capillaries) — the 99% of circulation most supplements ignore
- Supports nitric oxide production via dual pathway (L-citrulline and ViNitrox)
- Reduces capillary permeability and microvascular inflammation
- Validated using GlycoCheck™ device — non-invasive measurement of EGX thickness in sublingual microvessels
- Microvascular disease — not large artery occlusion — is the dominant driver of chronic cerebral hypoperfusion and white matter disease
- Restoring microvascular EGX may improve oxygen and nutrient delivery to vulnerable periventricular and deep white matter regions
- L-citrulline/nitric oxide pathway directly improves cerebral autoregulation
Arterosil vs. ReVasca — How They Complement Each Other
| Feature | Arterosil HP | ReVasca™ |
|---|---|---|
| Primary target | Large vessels, arteries, capillaries | Microvessels, capillary bed |
| Active compound | Rhamnan sulfate (heparan sulfate mimetic) | Hyaluronic acid, acemannan, fucoidan |
| Plaque regression data | Yes (carotid plaque case series, PMC 2024) | Microvascular data; plaque data pending |
| Nitric oxide support | Indirect (via EGX-dependent NOS activation) | Direct (L-citrulline, ViNitrox) |
| Validation tool | CIMT, MaxPulse, pulse wave analysis | GlycoCheck device (sublingual microvessels) |
| Evidence level | In vitro + small human case series + animal | Clinical instrument + predecessor (Endocalyx Pro) |
| FDA status | Dietary supplement (not FDA-approved drug) | Dietary supplement (not FDA-approved drug) |
| Combination use | Complementary — may be used together for comprehensive large and small vessel glycocalyx support | |
Evidence, Limitations, and Clinical Context
The MEND protocol represents a paradigm-shifting approach to Alzheimer's disease with compelling early results. It also has significant evidentiary limitations that clinicians must understand and communicate honestly to patients and families.
What the Evidence Supports
Limitations of Bredesen's Published Studies
- ▸ No methods section in any of the three published papers (2014, 2016, 2018)
- ▸ Case series design — no control group, no randomization
- ▸ No data on non-responders; potential for significant selection bias
- ▸ Lack of standardized diagnostic criteria — some "patients" had subjective, not objective, impairment
- ▸ Repeat testing effects may explain some cognitive score improvements
- ▸ Published in open-access journals with limited peer review scrutiny
- ▸ No dose or duration information for most interventions
- ▸ International consensus documents have not endorsed intensive supplement regimens for dementia prevention
What This Means for Clinical Practice
The MEND protocol should be presented to patients and staff in a balanced way:
Appropriate framing
- ▸ "This is a promising approach with compelling case reports"
- ▸ "Several components are evidence-based and should be done regardless"
- ▸ "The supplement regimen is investigational"
- ▸ "We don't yet have large RCT data to confirm efficacy"
- ▸ "The lifestyle components are low-risk and high-value"
Things to avoid
- ▸ Presenting MEND as a proven cure for AD
- ▸ Encouraging expensive supplement protocols without evidence discussion
- ▸ Giving false hope to patients with moderate-severe AD
- ▸ Replacing evidence-based treatments with MEND alone
- ▸ Dismissing it entirely — many components have independent support
Our Clinical Recommendation
Ongoing Research
As of 2024, Bredesen and Apollo Health are conducting a prospective clinical trial of the ReCODE 2.0 protocol. Results from this trial will be important in determining whether the protocol's benefits hold up under rigorous controlled conditions. A 2022 peer-reviewed clinical trial by Bredesen showed promising results, providing the first formal trial data for the approach.